Pharming Group NV said that it plans to appeal against the European Medicines Agency’s negative opinion for Rhucin, its proposed treatment for patients with acute attacks of hereditary angioedema (HAE). The opinion was delivered on 13 December 2007 by the agency’s main scientific committee, the Committee for Medicinal Products for Human Use (CHMP).
